Seeking Alpha

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has...

Baird defends Regeneron (REGN -2.1%) this morning, saying the drug developer's downstream has significant potential. The firm cites the beginning of REGN's Phase lll testing of REGN727 next month, plus FDA guidance that cardiovascular outcomes will not be a prerequisite for approval.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)